Shots: Medicure is responsible for the regulatory approval process for the product The agreement grants an exclusive right to Medicure to market & sell the product in the US, Canada […]readmore
Tags : Cardiovascular
Shots: The P-II study involves assessing AKCEA-ANGPTL3-LRx (SC, 40-80mg) vs PBO in 105 patients with hypertriglyceridemia, T2D, and NAFLD for 6mos. The P-II study resulted in meeting its primary & […]readmore
Shots: Exscientia to get up to $266.2M including upfront, research payments and clinical milestones plus royalties on sales. Bayer to get rights for the developed therapies under collaboration The […]readmore
Shots: Bayer signs an option, research and license agreement with Dewpoint’s to develop therapies for cardiovascular and gynecological diseases and will contribute up to $100M. Bayer will get an option […]readmore
Shots: Baxter’s ready to use Eptifibatide is approved and launched for patients with acute coronary syndrome (ACS) & percutaneous coronary intervention (PCI) The FDA approval strengthens Baxter’s premix portfolio, enhance […]readmore
Shots: The expanded indication approval is based on the results of P-III FOURIER study assessing Repatha (140mg q2w, 420 mg/month) vs PBO + statin therapy in patients with cardiovascular events […]readmore
Shots: The Study Watch has received FDA’s 510 (k) Clearance as a Class II medical device for its on-demand ECG feature The medical device is used for displaying single-channel ECG […]readmore